Technetium Mebrofenin

CHEMBL2110555 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Technetium mebrofenin (99mTc-mebrofenin) is a high-extraction hepatobiliary iminodiacetic acid radiopharmaceutical used for HIDA scintigraphy to evaluate hepatic function, gallbladder function, and biliary excretion with high liver-to-background contrast. It is particularly useful in patients with elevated bilirubin levels where other IDA agents may have insufficient hepatic extraction. It is used to diagnose acute cholecystitis, assess pre-operative liver function, and detect biliary leaks.

Mechanism of Action

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Technetium mebrofenin (99mTc-mebrofenin) is a high-extraction hepatobiliary iminodiacetic acid radiopharmaceutical used for HIDA scintigraphy to evaluate hepatic function, gallbladder function, and biliary excretion with high liver-to-background contrast. It is particularly useful in patients with elevated bilirubin levels where other IDA agents may have insufficient hepatic extraction. It is used to diagnose acute cholecystitis, assess pre-operative liver function, and detect biliary leaks.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Technetium Mebrofenin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2110555. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.